Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Alba Therapeutics

Request full access

Privately held, clinical-stage biopharmaceutical company

Baltimore, United StatesFounded 2004Biotech & Life Sciences

About Alba Therapeutics

Alba Therapeutics Corporation was a privately held, clinical-stage biopharmaceutical company established in 2004 and headquartered in Baltimore, Maryland. The company was co-founded by Dr. Blake M. Paterson, a former Eli Lilly executive, and Dr. Alessio Fasano, a professor and researcher at the University of Maryland School of Medicine. Dr. Fasano's research into the protein zonulin, which regulates the permeability of the intestinal barrier, formed the scientific foundation of the company. His work identified how modulating this pathway could be instrumental in treating autoimmune and inflammatory diseases. Dr. Paterson served as the initial CEO, securing over $40 million in funding, including a significant $30 million Series A round in August 2005 and an additional $10 million in venture debt in November 2006.

The company's primary focus was the development and commercialization of therapeutics for autoimmune, immune-mediated, and inflammatory diseases, with a particular emphasis on gastrointestinal disorders. Alba's business model centered on advancing its lead drug candidate through the rigorous phases of clinical trials to eventually gain regulatory approval and bring a first-in-class treatment to market. Its core technology was based on the zonulin pathway, which controls cellular barriers in tissues like the intestinal mucosa. By developing permeability inhibitors, Alba aimed to treat conditions associated with dysfunctional tight junctions, such as celiac disease and type 1 diabetes.

Alba's flagship product candidate was larazotide acetate (formerly AT-1001), an orally administered peptide designed to function as a zonulin receptor antagonist. For patients with celiac disease, ingestion of gluten triggers the release of zonulin, which loosens the tight junctions of the intestinal wall. This increased permeability allows gluten fragments to pass through, initiating an inflammatory cascade and the associated debilitating symptoms. Larazotide acetate was developed to prevent these tight junctions from opening, thereby inhibiting the inflammatory response to gluten. The drug successfully completed multiple clinical trials, including a Phase IIb study with 342 patients, showing promising results in reducing symptoms for celiac disease patients who were not fully responsive to a gluten-free diet. In February 2016, Alba Therapeutics licensed all assets related to larazotide acetate to Innovate Biopharmaceuticals Inc., which planned to advance the drug into Phase 3 trials. According to PitchBook, Alba Therapeutics is now out of business as of April 2016.

Source: Dealroom company data

At a glance

Founded
2004
Headquarters
Baltimore, United States
Sector
Biotech & Life Sciences

Alba Therapeutics in the Baltimore ecosystem

Live from Dealroom

The Alba Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • Alta Partners
  • SV Health Investors
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States88.9%
🇵🇪 Peru11.1%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Alba Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Alba Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.